Probity Advisors Inc. Has $217,000 Stock Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Probity Advisors Inc. raised its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 33.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 30,692 shares of the company’s stock after acquiring an additional 7,647 shares during the period. Probity Advisors Inc. owned approximately 0.05% of Health Catalyst worth $217,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Mackenzie Financial Corp acquired a new position in shares of Health Catalyst during the fourth quarter worth approximately $248,000. PharVision Advisers LLC bought a new position in Health Catalyst in the 4th quarter valued at about $185,000. Two Sigma Advisers LP lifted its position in Health Catalyst by 72.7% in the 4th quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock valued at $210,000 after acquiring an additional 12,500 shares in the last quarter. Two Sigma Investments LP bought a new position in Health Catalyst in the 4th quarter valued at about $496,000. Finally, ProShare Advisors LLC lifted its position in Health Catalyst by 52.7% in the 4th quarter. ProShare Advisors LLC now owns 16,854 shares of the company’s stock valued at $119,000 after acquiring an additional 5,815 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Insider Transactions at Health Catalyst

In other news, General Counsel Benjamin Landry sold 13,827 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the sale, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This trade represents a 7.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the sale, the chief operating officer now owns 216,250 shares of the company’s stock, valued at approximately $977,450. The trade was a 7.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 41,147 shares of company stock worth $182,284 in the last quarter. Insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

HCAT has been the topic of several recent research reports. Royal Bank of Canada dropped their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Citigroup dropped their price target on shares of Health Catalyst from $7.00 to $6.50 and set a “buy” rating on the stock in a research report on Friday, April 25th. Evercore ISI cut shares of Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday, April 9th. Stifel Nicolaus raised their price target on shares of Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a research report on Thursday, May 8th. Finally, Stephens dropped their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Health Catalyst Trading Up 3.6%

NASDAQ:HCAT opened at $3.78 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a market cap of $263.09 million, a price-to-earnings ratio of -2.80 and a beta of 1.56. Health Catalyst, Inc. has a 52 week low of $3.54 and a 52 week high of $9.24. The firm has a 50-day moving average price of $4.05 and a two-hundred day moving average price of $5.59.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.